Regeneron Pharmaceuticals (REGN) is "significantly undervalued" because the market remains overly focused on Eylea's sales erosion and struggles to appreciate the full value of the company's pipeline and Dupixent, RBC Capital Markets said in a note on Tuesday.
The firm said that even without Eylea, it expects Regeneron to have a fundamental floor valuation of $550 per share based on Dupixent, other commercial assets and cash, which is not reflected in current stock levels.
"Pulling out Eylea and related expenses unmasks the high leverage the company has to grow earnings in the medium term through Dupi expansion, pipeline, and the Sanofi (SNY) development expense payoff," RBC said.
The firm estimates Regeneron's ex-Eylea fair value to range between $716 and $1,289 per share and said pipeline readouts in the second half and beyond are expected to shift focus away from Eylea.
RBC has an outperform rating on Regeneron's stock with a price target of $943.
Price: 599.72, Change: +11.38, Percent Change: +1.93
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。